Module / Dose context
Tesamorelin Dosage: Doses Studied in the Trials
What was administered, to whom, by which route, and over how long — reported as research context, with no human dosing recommendation.
Read this first
This page reports the tesamorelin dosage used in the studies — not a protocol to follow. Across the major trials the studied amount was 2 milligrams a day, given as a small injection under the skin (subcutaneous) into the abdomen, once daily. A lower 1 mg amount appeared in a couple of specialized studies. The numbers below describe what researchers gave to trial participants — overwhelmingly HIV patients — and nothing here is a dose for personal use. Research-grade tesamorelin is supplied for laboratory work and is not the approved drug product.
Doses Studied in the Tesamorelin Trials
The tesamorelin dosage used across both pivotal Phase 3 trials, and in the FDA-approved regimen, was 2 mg administered subcutaneously once daily [1][2]. That is the extensively studied paradigm: the 26-week trial of 412 patients, the 52-week program, the JAMA hepatic-fat RCT, and the 2024 integrase-inhibitor-era trial all used 2 mg/day [1][2][3][13].
A lower 1 mg/day subcutaneous arm has been studied in narrower settings — a cognition trial in older adults and as a lower arm in a dedicated type-2-diabetes safety trial. Later product reformulations use a higher-concentration once-daily subcutaneous regimen, but the once-daily 2 mg paradigm is the one the efficacy literature rests on. Every figure here is framed as "studied at X mg/day in [population]" — a description of trial protocols, never a personal dosing instruction.
Route and Administration in the Studies
Every clinical trial used a single route: subcutaneous injection, at an abdominal site [1]. That is also the only FDA-approved route. No oral, intranasal, or other route appears in the efficacy record — tesamorelin is a peptide, and like other peptide hormones it is not orally bioavailable in a usable form.
The compound is supplied as a lyophilized (freeze-dried) powder requiring reconstitution before use. The FDA label specifies refrigerated storage and use of the reconstituted solution within a defined window. These are handling characteristics of the studied product, reported here as research context.
Why Once Daily Despite a Short Half-Life
The once-daily schedule is not arbitrary, and it is the dose question most worth understanding. Tesamorelin clears plasma quickly — population PK modeling reported an apparent clearance of about 1,060 L/h, and secondary sources describe a terminal half-life of roughly 26-38 minutes [1]. On its own, that brief exposure might suggest more frequent dosing.
What sustains the once-daily interval is the downstream effect. The IGF-1 elevation that tesamorelin triggers persists across the day even after the peptide itself has cleared, so a single daily dose maintains the biological signal [1]. The absorbed fraction also rose about 13% by day 14 versus day 1, with no clinically relevant demographic covariates [1]. The full pharmacokinetic picture sits in the tesamorelin half-life and pharmacokinetics module.
What the Dose Achieved in the Trials
At the studied 2 mg/day, the measurable outcomes were consistent: a 15.2% visceral-fat reduction at 26 weeks sustained to -18% at 52 weeks [1][2], an IGF-1 rise of 81.0% [1], and a pooled VAT reduction of -27.71 cm2 across five RCTs [12]. In healthy men, the same 2 mg/day raised mean overnight GH by 0.5 ug/L and IGF-1 by 181 ug/L over two weeks while preserving insulin sensitivity [4].
These results were all obtained in clinical-trial settings — overwhelmingly in HIV patients — under monitoring. They describe what the studied dose produced in those populations, not what any individual should take. The doses studied in the trials are reported strictly as the protocol parameters of the published research.